Stockscreener 앱 받기
11.66
3.97%
-0.3917
전일 마감가:
$12.05
열려 있는:
$11.97
하루 거래량:
312.00K
Relative Volume:
0.23
시가총액:
$1.15B
수익:
-
순이익/손실:
$-137.25M
주가수익비율:
-6.1684
EPS:
-1.89
순현금흐름:
$-121.97M
1주 성능:
-4.53%
1개월 성능:
+39.92%
6개월 성능:
-1.94%
1년 성능:
+11.91%
1일 변동 폭
$11.52
$12.10
1주일 범위
$11.33
$12.70
52주 변동 폭
$3.8951
$14.93
Oric Pharmaceuticals Inc Stock (ORIC) Company Profile
명칭
Oric Pharmaceuticals Inc
전화
(650) 388-5600
주소
240 E. GRAND AVE., SOUTH SAN FRANCISCO, CA
ORIC을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ORIC
Oric Pharmaceuticals Inc
|
11.81 | 1.17B | 0 | -137.25M | -121.97M | -1.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
467.81 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.12 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
830.70 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
362.33 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
342.01 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Oric Pharmaceuticals Inc Stock (ORIC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-07 | 개시 | Piper Sandler | Overweight |
| 2025-11-20 | 개시 | Evercore ISI | Outperform |
| 2025-11-18 | 개시 | Wolfe Research | Peer Perform |
| 2025-09-04 | 재개 | Guggenheim | Buy |
| 2025-07-08 | 개시 | Ladenburg Thalmann | Buy |
| 2024-10-31 | 개시 | Wells Fargo | Overweight |
| 2024-09-06 | 개시 | Stifel | Buy |
| 2024-02-23 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-09-22 | 개시 | Wedbush | Outperform |
| 2023-03-23 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2023-03-21 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-03-16 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2022-07-18 | 재개 | Oppenheimer | Perform |
| 2022-04-04 | 업그레이드 | Citigroup | Neutral → Buy |
| 2022-03-25 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2022-03-22 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-03-22 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2022-03-22 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2021-07-06 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-01-25 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-08-13 | 개시 | Robert W. Baird | Outperform |
| 2020-08-06 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-08-03 | 개시 | H.C. Wainwright | Buy |
| 2020-05-19 | 개시 | Citigroup | Neutral |
| 2020-05-19 | 개시 | Guggenheim | Buy |
| 2020-05-19 | 개시 | JP Morgan | Overweight |
| 2020-05-19 | 개시 | Jefferies | Buy |
모두보기
Oric Pharmaceuticals Inc 주식(ORIC)의 최신 뉴스
Oric Pharmaceuticals, Inc. (ORIC) Stock Analysis: 74% Potential Upside Sparks Investor Interest - DirectorsTalk Interviews
Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Oric Pharmaceuticals director Heyman sells shares worth $80,430 - Investing.com
ORIC Pharmaceuticals: Transition To Late-Stage Development Presents Upside - Seeking Alpha
Short Interest in Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Grows By 19.6% - MarketBeat
ORIC Pharmaceuticals (ORIC) Is Up 32.5% After J&J Lung Cancer Collaboration and Pipeline UpdateWhat's Changed - Sahm
ORIC Pharmaceuticals Stock Pre-Market (-6.1%) : Form 144 Filings Signal Intent to Sell - Trefis
First Week of March 20th Options Trading For Oric Pharmaceuticals (ORIC) - Nasdaq
Volume Summary: Is ORIC Pharmaceuticals Inc forming higher highs and higher lows2025 Analyst Calls & Fast Gaining Stock Strategy Reports - baoquankhu1.vn
Is Roma Green Finance Limited gaining market shareJuly 2025 Trends & Free Community Consensus Stock Picks - baoquankhu1.vn
Assessing ORIC Pharmaceuticals (ORIC) Valuation After Fresh Buy Ratings And Johnson & Johnson Collaboration - Sahm
Why ORIC Pharmaceuticals (ORIC) Is Up 36.3% After New Cancer Data And Analyst Buzz - Yahoo Finance
H.C. Wainwright reiterates Buy rating on ORIC Pharmaceuticals stock By Investing.com - Investing.com Canada
ORIC Pharmaceuticals provides 2025 operational highlights, upcoming milestones - MSN
Oric Pharmaceuticals (NASDAQ:ORIC) Sees Large Volume IncreaseStill a Buy? - MarketBeat
Precision Killers: Why Big Pharma is Betting Billions to Beat a $170B Patent Cliff - marketscreener.com
ORIC: Advancing two late-stage oncology drugs with pivotal data and trials expected by 2027 - TradingView — Track All Markets
Wedbush Reaffirms Outperform Rating for Oric Pharmaceuticals (NASDAQ:ORIC) - MarketBeat
Wedbush Reiterates Outperform Rating for ORIC at $20 | ORIC Stoc - GuruFocus
ORIC Pharmaceuticals reports progress on cancer drug candidates By Investing.com - Investing.com Nigeria
(ORIC) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
ORIC Pharmaceuticals reports progress on cancer drug candidates - Investing.com
ORIC® Pharmaceuticals Provides Operational Highlights for 2025 and Anticipated Upcoming Milestones - Sahm
Oric Pharmaceuticals (NASDAQ:ORIC) Earns Overweight Rating from Analysts at Piper Sandler - Defense World
Oric Pharmaceuticals (NASDAQ:ORIC) Trading 7.8% HigherShould You Buy? - MarketBeat
Oric Pharmaceuticals, Inc. (ORIC) Stock Analysis: A Biotech Gem with 148% Upside Potential - DirectorsTalk Interviews
Oric Pharmaceuticals (NASDAQ:ORIC) Upgraded by Piper Sandler to Strong-Buy Rating - MarketBeat
Why ORIC Pharmaceuticals Inc. stock attracts global investors2025 Price Targets & High Win Rate Trade Alerts - Улправда
Is ORIC Pharmaceuticals Inc. stock a buy before product launchesQuarterly Trade Report & Capital Efficient Trading Techniques - Улправда
Will ORIC Pharmaceuticals Inc. (4TZ) stock gain from green policiesEarnings Miss & Stock Timing and Entry Methods - Улправда
Options Flow: Will ORIC Pharmaceuticals Inc. (4TZ) stock gain from green policies2025 EndofYear Setup & Daily Technical Stock Forecast Reports - ulpravda.ru
Oric Pharmaceuticals (NASDAQ:ORIC) Shares Gap UpWhat's Next? - MarketBeat
How ORIC Pharmaceuticals Inc. stock reacts to Fed rate cutsVolatility Trading Techniques & Superior Capital Trading Plans - ulpravda.ru
Piper Sandler Initiates Coverage on ORIC with Overweight Rating and $22 PT | ORIC Stock News - GuruFocus
Piper Sandler initiates ORIC Pharmaceuticals stock with Overweight rating By Investing.com - Investing.com Canada
Piper Sandler initiates ORIC Pharmaceuticals stock with Overweight rating - Investing.com India
ORIC® Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
ORIC Pharmaceuticals shares surge on potential data leak - MSN
Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Oric Pharmaceuticals’ 2025 Restructuring: Potential Risks and Financial Implications - MSN
How to Invest in the U.S. Biotech Sector in 2026? Jefferies: Focus on These 6 Top Picks, 7 High-Potential Stocks, and 5 Key Acquisition Targets - Futubull
Squarepoint Ops LLC Invests $1.08 Million in Oric Pharmaceuticals, Inc. $ORIC - Defense World
(ORIC) and the Role of Price-Sensitive Allocations - Stock Traders Daily
ORIC Pharmaceuticals (ORIC) surges as intriguing ESMO Asia data for Enozertinib prompts Wells Fargo to assign higher value - MSN
Will ORIC Pharmaceuticals Inc. stock benefit from green energy trendsWatch List & AI Optimized Trading Strategy Guides - Улправда
Is ORIC Pharmaceuticals Inc. stock a buy on dipsDollar Strength & Growth-Oriented Investment Plans - DonanımHaber
Why retail investors favor ORIC Pharmaceuticals Inc. stockMarket Activity Report & Weekly Stock Breakout Alerts - DonanımHaber
How ORIC Pharmaceuticals Inc. stock reacts to job market dataExit Point & High Yield Stock Recommendations - DonanımHaber
Will ORIC Pharmaceuticals Inc. stock benefit from infrastructure spendingDividend Hike & Free Technical Confirmation Trade Alerts - DonanımHaber
Oric Pharmaceuticals (ORIC) Stock Analysis: Exploring a 157% Upside Potential in the Biotech Arena - DirectorsTalk Interviews
Oric Pharmaceuticals Inc (ORIC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Oric Pharmaceuticals Inc 주식 (ORIC) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Heyman Richard A. | Director |
Jan 16 '26 |
Sale |
12.00 |
3,200 |
38,415 |
213,072 |
2.39%
1.60%
자본화:
|
볼륨(24시간):